. home.aspx

NEWS

home.aspx
   


Neuropore Therapies Receives $500,000 Grant from The ALS Association

February 17, 2020 / BioSpace
SHARESHARESHARE

Neuropore Therapies, Inc., a biopharmaceutical company discovering and developing novel therapeutics for the treatment of neurodegenerative disorders, announced today that it has been awarded a $500,000 grant from The ALS Association to support the preclinical evaluation and development of its leading Toll-Like Receptor 2 (TLR2) antagonist NPT1220-312 for the treatment of amyotrophic lateral sclerosis. The grant has been made through the Association’s Lawrence and Isabel Barnett Drug Development Program.